PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
NASDAQ:PCRX - Nasdaq - US6951271005 - Common Stock - Currency: USD
Taking everything into account, PCRX scores 5 out of 10 in our fundamental rating. PCRX was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of PCRX get a neutral evaluation. Nothing too spectacular is happening here. PCRX is cheap, but on the other hand it scores bad on growth. This makes PCRX very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
PCRX had a positive operating cash flow in the past year.
PCRX had positive earnings in 4 of the past 5 years.
PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -8.29%, PCRX is in the better half of the industry, outperforming 69.95% of the companies in the same industry.
PCRX has a Return On Equity of -16.82%. This is in the better half of the industry: PCRX outperforms 71.50% of its industry peers.
PCRX has a Return On Invested Capital of 3.88%. This is amongst the best in the industry. PCRX outperforms 80.31% of its industry peers.
PCRX had an Average Return On Invested Capital over the past 3 years of 4.17%. This is significantly below the industry average of 15.57%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROIC | 3.88% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
1.3 Margins
The Operating Margin of PCRX (9.90%) is better than 81.87% of its industry peers.
In the last couple of years the Operating Margin of PCRX has grown nicely.
Looking at the Gross Margin, with a value of 78.19%, PCRX belongs to the top of the industry, outperforming 85.49% of the companies in the same industry.
PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% |
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PCRX has been reduced compared to 1 year ago.
PCRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PCRX has a worse debt to assets ratio.
2.2 Solvency
PCRX has an Altman-Z score of 1.65. This is a bad value and indicates that PCRX is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.65, PCRX is doing good in the industry, outperforming 62.69% of the companies in the same industry.
PCRX has a debt to FCF ratio of 4.96. This is a neutral value as PCRX would need 4.96 years to pay back of all of its debts.
The Debt to FCF ratio of PCRX (4.96) is better than 82.90% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that PCRX is not too dependend on debt financing.
PCRX has a worse Debt to Equity ratio (0.50) than 60.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Altman-Z | 1.65 |
ROIC/WACC0.45
WACC8.66%
2.3 Liquidity
PCRX has a Current Ratio of 2.38. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PCRX (2.38) is comparable to the rest of the industry.
PCRX has a Quick Ratio of 1.91. This is a normal value and indicates that PCRX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of PCRX (1.91) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 |
3. Growth
3.1 Past
The earnings per share for PCRX have decreased by -1.92% in the last year.
Measured over the past years, PCRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.96% on average per year.
PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.68%.
Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
3.2 Future
PCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.84% yearly.
PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.56% yearly.
EPS Next Y-7.79%
EPS Next 2Y2.91%
EPS Next 3Y9.01%
EPS Next 5Y5.84%
Revenue Next Year6%
Revenue Next 2Y8.48%
Revenue Next 3Y8.65%
Revenue Next 5Y6.56%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.30, the valuation of PCRX can be described as very reasonable.
92.75% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (26.76), we can say PCRX is valued rather cheaply.
A Price/Forward Earnings ratio of 7.47 indicates a rather cheap valuation of PCRX.
90.16% of the companies in the same industry are more expensive than PCRX, based on the Price/Forward Earnings ratio.
PCRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.91.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.3 | ||
| Fwd PE | 7.47 |
4.2 Price Multiples
92.23% of the companies in the same industry are more expensive than PCRX, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 90.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.04 | ||
| EV/EBITDA | 7.17 |
4.3 Compensation for Growth
PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.59
EPS Next 2Y2.91%
EPS Next 3Y9.01%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
25.39
+0.4 (+1.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners111.46%
Inst Owner Change0.19%
Ins Owners0.8%
Ins Owner Change0.71%
Market Cap1.18B
Analysts76.92
Price Target39.78 (56.68%)
Short Float %12.52%
Short Ratio8.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.06%
Min EPS beat(2)1.99%
Max EPS beat(2)2.13%
EPS beat(4)4
Avg EPS beat(4)5.22%
Min EPS beat(4)1.99%
Max EPS beat(4)9.93%
EPS beat(8)5
Avg EPS beat(8)3.99%
EPS beat(12)6
Avg EPS beat(12)-0.53%
EPS beat(16)8
Avg EPS beat(16)-3.68%
Revenue beat(2)0
Avg Revenue beat(2)-4.46%
Min Revenue beat(2)-5.92%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-2.98%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.49%
Revenue beat(12)1
Avg Revenue beat(12)-2.62%
Revenue beat(16)1
Avg Revenue beat(16)-2.55%
PT rev (1m)1.04%
PT rev (3m)0%
EPS NQ rev (1m)-1.5%
EPS NQ rev (3m)-24.83%
EPS NY rev (1m)0%
EPS NY rev (3m)2.92%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)0.51%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.3 | ||
| Fwd PE | 7.47 | ||
| P/S | 1.67 | ||
| P/FCF | 10.04 | ||
| P/OCF | 8.74 | ||
| P/B | 1.55 | ||
| P/tB | 3.73 | ||
| EV/EBITDA | 7.17 |
EPS(TTM)3.06
EY12.05%
EPS(NY)3.4
Fwd EY13.39%
FCF(TTM)2.53
FCFY9.96%
OCF(TTM)2.91
OCFY11.44%
SpS15.25
BVpS16.37
TBVpS6.8
PEG (NY)N/A
PEG (5Y)0.59
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROCE | 5.71% | ||
| ROIC | 3.88% | ||
| ROICexc | 6.11% | ||
| ROICexgc | 14.17% | ||
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% | ||
| FCFM | 16.59% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
ROICexc(3y)5.86%
ROICexc(5y)7.17%
ROICexgc(3y)13.2%
ROICexgc(5y)24.66%
ROCE(3y)6.13%
ROCE(5y)6.57%
ROICexcg growth 3Y-34.27%
ROICexcg growth 5Y13.31%
ROICexc growth 3Y-4.56%
ROICexc growth 5Y9.22%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 19.4% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 4.34 | ||
| Cash Conversion | 84.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 | ||
| Altman-Z | 1.65 |
F-Score5
WACC8.66%
ROIC/WACC0.45
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
EPS Next Y-7.79%
EPS Next 2Y2.91%
EPS Next 3Y9.01%
EPS Next 5Y5.84%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
Revenue Next Year6%
Revenue Next 2Y8.48%
Revenue Next 3Y8.65%
Revenue Next 5Y6.56%
EBIT growth 1Y-39.89%
EBIT growth 3Y-9.76%
EBIT growth 5Y22.27%
EBIT Next Year1.75%
EBIT Next 3Y12.4%
EBIT Next 5Y6.85%
FCF growth 1Y-7.53%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-8.67%
OCF growth 3Y14.64%
OCF growth 5Y21.85%